MedTrace Logo

Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease

NCT05305833 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-03-31

No results posted yet for this study

Summary

It will be evaluate the safety of mesenchymal stem cells and adipose tissue derived stromal vascular fraction (SVF) in temporomandibular joint disease cases.

Conditions

  • Temporomandibular Joint Disorders
  • Temporomandibular Disorder
  • Temporomandibular Joint Osteoarthritis
  • Temporomandibular Joint Pain
  • Temporomandibular Joint Effusion

Interventions

BIOLOGICAL

Stem Cells

ATMP

Sponsors & Collaborators

  • TC Erciyes University

    lead OTHER

Principal Investigators

  • Zeynep B Gonen, DDS,PHD · Assoc.Prof

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-12-01
Completion
2023-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305833 on ClinicalTrials.gov